The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer

BACKGROUND: To date, immunotherapy has improved the 5-year survival rate of patients with advanced non-small cell lung cancer (NSCLC) from 4% to 15%. However, only 30%-50% of the NSCLC patients respond to immune checkpoint inhibitors (ICIs) immunotherapy. Therefore, screening patients for potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Hao, Tong, Fan, Bin, Yawen, Peng, Ling, Gao, Xuan, Xia, Xuefeng, Yi, Xin, Dong, Xiaorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886445/
https://www.ncbi.nlm.nih.gov/pubmed/35242138
http://dx.doi.org/10.3389/fimmu.2022.834142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886445/
https://www.ncbi.nlm.nih.gov/pubmed/35242138
http://dx.doi.org/10.3389/fimmu.2022.834142

Ejemplares similares